Overview Dividends

(CME) CME - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US12572Q1058

Futures, Options, Swaps, Data Services, Clearing Services

CME EPS (Earnings per Share)

EPS Growth (3Y CAGR): 15.47%
EPS Trend (3Y Correlation): 85.8%

CME Revenue

Revenue Growth (3Y CAGR): 12.37%
Revenue Trend (3Y Correlation): 93.3%

Description: CME CME

CME Group Inc. is a leading global exchange company that operates contract markets for trading futures and options on futures contracts. The company offers a diverse range of products, including interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, catering to various market participants such as professional traders, financial institutions, and individual investors.

As a critical infrastructure provider, CME Groups clearing house services ensure the stability and integrity of the financial markets by clearing, settling, and guaranteeing futures and options contracts. The companys market data services also play a crucial role in providing real-time and historical data to market participants, enabling informed decision-making.

From a performance perspective, CME Group has demonstrated strong financials, with a Return on Equity (RoE) of 13.14%. The companys market capitalization stands at approximately $99.25 billion, indicating its significant presence in the financial exchanges and data industry. Key Performance Indicators (KPIs) such as revenue growth, average daily volume (ADV), and open interest can be used to further evaluate the companys operational performance.

Some additional KPIs that can be used to assess CME Groups performance include its clearing and transaction fees revenue, market data revenue, and the growth of its cleared swaps products. The companys ability to expand its product offerings, enhance its technology infrastructure, and maintain its competitive edge in the market will be crucial in driving its future growth.

CME Stock Overview

Market Cap in USD	98,964m
Sub-Industry	Financial Exchanges & Data
IPO / Inception	2002-12-06

CME Stock Ratings

Growth Rating	77.5%
Fundamental	75.9%
Dividend Rating	68.0%
Return 12m vs S&P 500	10.1%
Analyst Rating	3.39 of 5

CME Dividends

Dividend Yield 12m	2.79%
Yield on Cost 5y	5.02%
Annual Growth 5y	12.00%
Payout Consistency	92.1%
Payout Ratio	87.1%

CME Growth Ratios

Growth Correlation 3m	4.1%
Growth Correlation 12m	94.6%
Growth Correlation 5y	74.8%
CAGR 5y	13.28%
CAGR/Max DD 5y	0.42
Sharpe Ratio 12m	1.81
Alpha	25.56
Beta	0.117
Volatility	19.19%
Current Volume	1753.3k
Average Volume 20d	1738.7k
Stop Loss	258.7 (-3%)
Signal	-1.46

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (3.76b TTM) > 0 and > 6% of Revenue (6% = 386.6m TTM)

FCFTA 0.02 (>2.0%) and ΔFCFTA -0.55pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 41.21% (prev 30.61%; Δ 10.60pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.02 (>3.0%) and CFO 4.20b > Net Income 3.76b (YES >=105%, WARN >=100%)

Net Debt (1.44b) to EBITDA (5.35b) ratio: 0.27 <= 3.0 (WARN <= 3.5)

Current Ratio 1.02 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (360.3m) change vs 12m ago 0.12% (target <= -2.0% for YES)

Gross Margin 86.53% (prev 85.70%; Δ 0.83pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 4.25% (prev 4.70%; Δ -0.45pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 30.10 (EBITDA TTM 5.35b / Interest Expense TTM 166.6m) >= 6 (WARN >= 3)

Altman Z'' 0.45

(A) 0.01 = (Total Current Assets 145.45b - Total Current Liabilities 142.79b) / Total Assets 179.91b

(B) 0.03 = Retained Earnings (Balance) 5.25b / Total Assets 179.91b

(D) 0.03 = Book Value of Equity 5.30b / Total Liabilities 152.17b

Total Rating: 0.45 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 75.89

1. Piotroski 4.0pt = -1.0

2. FCF Yield 1.69% = 0.84

3. FCF Margin 63.74% = 7.50

4. Debt/Equity 5.27 = -2.50

5. Debt/Ebitda 27.34 = -2.50

6. ROIC - WACC 10.03% = 12.50

7. RoE 13.72% = 1.14

8. Rev. Trend 93.25% = 4.66

9. Rev. CAGR 12.37% = 1.55

10. EPS Trend 85.82% = 2.15

11. EPS CAGR 15.47% = 1.55

What is the price of CME shares?

As of August 29, 2025, the stock is trading at USD 266.77 with a total of 1,753,278 shares traded.
Over the past week, the price has changed by -2.40%, over one month by -2.68%, over three months by -6.29% and over the past year by +29.60%.

Is CME a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, CME (NASDAQ:CME) is currently (August 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 75.89 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CME is around 294.35 USD . This means that CME is currently undervalued and has a potential upside of +10.34% (Margin of Safety).

Is CME a buy, sell or hold?

CME has received a consensus analysts rating of 3.39. Therefor, it is recommend to hold CME.

Strong Buy: 4
Buy: 3
Hold: 7
Sell: 4
Strong Sell: 0

What are the forecasts/targets for the CME price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	283.1	6.1%
Analysts Target Price	271.1	1.6%
ValueRay Target Price	310.9	16.5%

Last update: 2025-08-21 11:13

CME Fundamental Data Overview

Market Cap USD = 98.96b (98.96b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 2.10b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 26.6095
P/E Forward = 24.6305
P/S = 15.3845
P/B = 3.5272
P/EG = 6.041
Beta = 0.457
Revenue TTM = 6.44b USD
EBIT TTM = 5.02b USD
EBITDA TTM = 5.35b USD
Long Term Debt = 3.42b USD (from longTermDebt, last quarter)
Short Term Debt = 142.79b USD (from totalCurrentLiabilities, last quarter)
Debt = 146.22b USD (Calculated: Short Term 142.79b + Long Term 3.42b)
Net Debt = 1.44b USD (from netDebt column, last quarter)
Enterprise Value = 243.08b USD (98.96b + Debt 146.22b - CCE 2.10b)
Interest Coverage Ratio = 30.10 (Ebit TTM 5.02b / Interest Expense TTM 166.6m)
FCF Yield = 1.69% (FCF TTM 4.11b / Enterprise Value 243.08b)
FCF Margin = 63.74% (FCF TTM 4.11b / Revenue TTM 6.44b)
Net Margin = 58.28% (Net Income TTM 3.76b / Revenue TTM 6.44b)
Gross Margin = 86.53% ((Revenue TTM 6.44b - Cost of Revenue TTM 867.9m) / Revenue TTM)
Tobins Q-Ratio = 45.83 (Enterprise Value 243.08b / Book Value Of Equity 5.30b)
Interest Expense / Debt = 0.03% (Interest Expense 44.0m / Debt 146.22b)
Taxrate = 22.36% (from yearly Income Tax Expense: 1.02b / 4.54b)
NOPAT = 3.89b (EBIT 5.02b * (1 - 22.36%))
Current Ratio = 1.02 (Total Current Assets 145.45b / Total Current Liabilities 142.79b)
Debt / Equity = 5.27 (Debt 146.22b / last Quarter total Stockholder Equity 27.74b)
Debt / EBITDA = 27.34 (Net Debt 1.44b / EBITDA 5.35b)
Debt / FCF = 35.60 (Debt 146.22b / FCF TTM 4.11b)
Total Stockholder Equity = 27.37b (last 4 quarters mean)
RoA = 2.09% (Net Income 3.76b, Total Assets 179.91b )
RoE = 13.72% (Net Income TTM 3.76b / Total Stockholder Equity 27.37b)
RoCE = 16.29% (Ebit 5.02b / (Equity 27.37b + L.T.Debt 3.42b))
RoIC = 12.64% (NOPAT 3.89b / Invested Capital 30.79b)
WACC = 2.62% (E(98.96b)/V(245.18b) * Re(6.45%)) + (D(146.22b)/V(245.18b) * Rd(0.03%) * (1-Tc(0.22)))
Shares Correlation 5-Years: 100.0 | Cagr: 0.09%
Discount Rate = 6.45% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 80.02% ; FCFE base≈3.86b ; Y1≈4.38b ; Y5≈5.99b
Fair Price DCF = 287.7 (DCF Value 103.69b / Shares Outstanding 360.4m; 5y FCF grow 15.74% → 3.0% )
Revenue Correlation: 93.25 | Revenue CAGR: 12.37%
Rev Growth-of-Growth: -0.76
EPS Correlation: 85.82 | EPS CAGR: 15.47%
EPS Growth-of-Growth: -0.08

Additional Sources for CME Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle